Lv11
10 积分 2023-02-25 加入
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
3小时前
待确认
Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate
1个月前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
1个月前
已完结
Cryoablation Activates the cGAS–STING‐CXCL10 Axis in Macrophages to Enhance Anti‐Tumor Immunity in NSCLC
2个月前
已完结
PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence
6个月前
已完结
[Chinese experts consensus on the diagnosis and management of checkpoint inhibitor pneumonitis(2025)]
7个月前
已完结
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
7个月前
已完结
Twenty-years experience withde novometastatic breast cancer
8个月前
已完结
Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics
8个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
8个月前
已完结
皖公网安备34019202002308
